Early safety check for experimental mental health drug
NCT ID NCT07549581
First seen May 01, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This early-stage study tested a new oral drug called SEP-380135 in 43 adults with schizophrenia or major depression (including bipolar disorder). The main goal was to check if the drug is safe and how the body processes it. Researchers measured side effects, vital signs, and mood changes over time. This trial does not prove the drug works, but it helps decide if larger studies should move forward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Collaborative Neuroscience Research, LLC
Los Alamitos, California, 90720, United States
Conditions
Explore the condition pages connected to this study.